Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending?
نویسندگان
چکیده
BACKGROUND Guidelines recommend screening for cervical cancer among women 30 years or older 3 years after a normal Papanicolaou test (hereinafter referred to as Pap test) result or a combined normal screening result (normal Pap/negative human papillomavirus [HPV] test results). We assessed reported recommendations by US primary care physicians (PCPs) on screening intervals that incorporate HPV cotesting compared with Pap testing alone. METHODS From September 1, 2006, through May 31, 2007, we conducted a mailed survey of a representative sample of 1212 PCPs, of whom 950 performed Pap tests and recommended the HPV test for screening or management. The main outcome measure included self-reported data on timing of screening intervals for women with normal results using clinical vignettes. RESULTS Among Pap test providers who recommend HPV testing, 31.8% reported that they would conduct the next Pap test in 3 years for a 35-year-old woman with 3 normal Pap test results. For a 35-year-old woman with a normal Pap test result and a negative HPV test finding, only 19.0% would conduct the next Pap test in 3 years. Most remaining physicians would conduct the Pap test more frequently. Most PCPs did not recommend a second HPV test or recommended the next HPV test at the same frequency as the Pap test. Physician specialty was strongly associated with guideline-consistent recommendations for the next Pap or HPV test. CONCLUSIONS A lower proportion of PCPs recommend extending screening intervals to 3 years with an HPV cotest than those screening with the Pap test alone. Implementation of effective interventions and strategies that improve physician adherence to recommendations will be important for efficient screening practices.
منابع مشابه
Pnm-17: Cost Effectiveness of Human Papillomavirus Testing in Cervical Cancer Diagnosis
Background: Epidemiological studies are shown robust association between human papillomavirus (HPV) and cervical cancer. From 1990 HPV was known as a necessary but insufficient cause of cervical invasive cancer. The purpose of this study was to evaluate the cost effectiveness of HPV test in cervical cancer screening. Materials and Methods: This is a systematic review article; the newest scienti...
متن کاملA new generation of studies of human papillomavirus DNA testing in cervical cancer screening.
JNCI Vol. 101, Issue 23 | December 2, 2009 “All zoogles are boogles. You saw a boogle. Is it a zoogle?” Question in an SAT examination (Nassim Nicholas Taleb in “The Black Swan”) “Not necessarily” is the resounding answer to this thought experiment, in analogy to the central argument in the debate on the clinical utility of human papillomavirus (HPV) testing in cervical cancer screening. Virtua...
متن کاملHow often should we screen for cervical cancer?
Over the past 60 years, the mortality from cervical cancer — once one of the most common and lethal cancers in women in the United States — has decreased dramatically. Much of the reduction has been due to the widespread use of the Papanicolaou test, which has enabled clinicians to detect cervical intraepithelial neoplasia before it progresses to cervical cancer and to detect cervical cancer at...
متن کاملA Multicountry Evaluation of careHPV Testing, Visual Inspection With Acetic Acid, and Papanicolaou Testing for the Detection of Cervical Cancer
OBJECTIVE This study evaluates the feasibility and performance of careHPV, a novel human papillomavirus (HPV) DNA test, when used for screening women for cervical cancer in low-resource settings. METHODS AND MATERIALS Clinician-collected (cervical) and self-collected (vaginal) careHPV specimens, visual inspection with acetic acid (VIA), and Papanicolaou test were evaluated among 16,951 eligib...
متن کاملCervical cancer screening: Less testing, smarter testing.
In its 2009 recommendations for cervical cancer screening, the American College of Obstetricians and Gynecologists (ACOG) calls for less-frequent but smarter screening that integrates testing for human papillomavirus (HPV) infection with the Papanicolaou (Pap) test. We review the recommendations from this and other organizations and how and why they are evolving.
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Archives of internal medicine
دوره 170 11 شماره
صفحات -
تاریخ انتشار 2010